152 related articles for article (PubMed ID: 24443104)
1. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.
Malouf GG; Job S; Paradis V; Fabre M; Brugières L; Saintigny P; Vescovo L; Belghiti J; Branchereau S; Faivre S; de Reyniès A; Raymond E
Hepatology; 2014 Jun; 59(6):2228-37. PubMed ID: 24443104
[TBL] [Abstract][Full Text] [Related]
2. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
3. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.
Malouf GG; Tahara T; Paradis V; Fabre M; Guettier C; Yamazaki J; Long H; Lu Y; Raynal NJ; Jelinek J; Mouawad R; Khayat D; Brugières L; Raymond E; Issa JP
Epigenetics; 2015; 10(9):872-81. PubMed ID: 26224146
[TBL] [Abstract][Full Text] [Related]
4. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
[TBL] [Abstract][Full Text] [Related]
5. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.
Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P
Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380
[TBL] [Abstract][Full Text] [Related]
7. Review of the clinicopathologic features of fibrolamellar carcinoma.
Torbenson M
Adv Anat Pathol; 2007 May; 14(3):217-23. PubMed ID: 17452818
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases.
Górnicka B; Ziarkiewicz-Wróblewska B; Wróblewski T; Wilczynski GM; Koperski L; Krawczyk M; Wasiutynski A
Hepatogastroenterology; 2005; 52(62):519-23. PubMed ID: 15816470
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization.
Wilkens L; Bredt M; Flemming P; Kubicka S; Klempnauer J; Kreipe H
Am J Clin Pathol; 2000 Dec; 114(6):867-74. PubMed ID: 11338475
[TBL] [Abstract][Full Text] [Related]
10. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review.
Vecchio FM
Appl Pathol; 1988; 6(2):139-48. PubMed ID: 2839216
[TBL] [Abstract][Full Text] [Related]
11. [A histopathologic comparative study of European cases of fibrolamellar carcinoma and Japanese cases of sclerosing hepatocellular carcinoma].
Haratake J; Horie A
Gan No Rinsho; 1989 Jun; 35(7):793-8. PubMed ID: 2544750
[TBL] [Abstract][Full Text] [Related]
12. [A particular hepatocellular carcinoma combining the ordinary and the fibrolamellar variant].
Zermani R; Charfi L; Kourda N; Farah F; Rammeh S; Trabelsi O; Zaouch A; Ben Jilani S
Tunis Med; 2005 Jul; 83(7):419-21. PubMed ID: 16220700
[TBL] [Abstract][Full Text] [Related]
13. [Surgical therapy of hepatic fibrolamellar carcinoma].
Meriggi F; Forni E
Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
16. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
[TBL] [Abstract][Full Text] [Related]
17. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
[TBL] [Abstract][Full Text] [Related]
18. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways.
Kannangai R; Vivekanandan P; Martinez-Murillo F; Choti M; Torbenson M
Hum Pathol; 2007 Apr; 38(4):639-44. PubMed ID: 17367606
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling.
Ueda T; Honda M; Horimoto K; Aburatani S; Saito S; Yamashita T; Sakai Y; Nakamura M; Takatori H; Sunagozaka H; Kaneko S
Genomics; 2013 Apr; 101(4):238-48. PubMed ID: 23485556
[TBL] [Abstract][Full Text] [Related]
20. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report.
Okano A; Hajiro K; Takakuwa H; Kobashi Y
Am J Gastroenterol; 1998 Jul; 93(7):1144-5. PubMed ID: 9672347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
